Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma

80Citations
Citations of this article
46Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Introduction: To depict the genomic landscape of Chinese early-stage lung squamous cell carcinoma (LUSC) and investigate its correlation with tumor mutation burden (TMB), PD-L1 expression, and immune infiltrates. Methods: Whole-exome sequencing was performed on 189 surgically resected LUSC. TMB was defined as the sum of nonsynonymous single nucleotide and indel variants. CD8+ tumor-infiltrating lymphocyte (TIL) density and PD-L1 expression were evaluated by immunohistochemistry. Six immune infiltrates were estimated using an online database. Results: The median TMB was 9.43 mutations per megabase. Positive PD-L1 expression and CD8+ TILs density were identified in 24.3% and 78.8%. PIK3CA amplification was associated with significantly higher TMB (P = 0.036). Frequent genetic alterations had no impact on PD-L1 expression but PIK3CA amplification and KEAP1 mutation were independently associated with significantly lower CD8+ TIL density (P < 0.001, P = 0.005, respectively). Low TMB and high CD8+ TIL density were independently associated with longer disease-free survival (DFS) while none of them could individually predict the overall survival (OS). Combination of TMB and PD-L1 expression or TMB and CD8+ TIL density could stratify total populations into two groups with distinct prognosis. Classifying tumor-immune microenvironment based on PD-L1 expression and CD8+ TIL density showed discrepant genomic alterations but similar TMB, clinical features, and OS. Notably, patients with different smoking status had distinct prognostic factors. Conclusion: The combination of TMB, PD-L1 expression, immune infiltrates, and smoking status showed the feasibility to subgroup stratification in Chinese patients with early-stage LUSC, which might be helpful for future design of personalized immunotherapy trials in LUSC.

References Powered by Scopus

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

8121Citations
N/AReaders
Get full text

Signatures of mutational processes in human cancer

7487Citations
N/AReaders
Get full text

Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer

7301Citations
N/AReaders
Get full text

Cited by Powered by Scopus

RNA sequencing: new technologies and applications in cancer research

330Citations
N/AReaders
Get full text

The cutting-edge progress of immune-checkpoint blockade in lung cancer

136Citations
N/AReaders
Get full text

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker

133Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Jiang, T., Shi, J., Dong, Z., Hou, L., Zhao, C., Li, X., … Zhou, C. (2019). Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. Journal of Hematology and Oncology, 12(1). https://doi.org/10.1186/s13045-019-0762-1

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 12

63%

Researcher 4

21%

Professor / Associate Prof. 2

11%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 11

46%

Biochemistry, Genetics and Molecular Bi... 7

29%

Agricultural and Biological Sciences 4

17%

Engineering 2

8%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free